Pancreatic Cancer

1. Clinical Overview

Summary

Pancreatic Ductal Adenocarcinoma (PDAC) represents approximately 95% of all pancreatic malignancies and is the 4th leading cause of cancer-related mortality in Western countries, with a devastating 5-year survival rate of only 7-9%. [1,2] This aggressive malignancy is characterized by late presentation, early metastatic dissemination, and profound resistance to conventional therapies. The pancreas's retroperitoneal location and absence of a sensory capsule permit silent tumor growth; consequently, 80-85% of patients present with locally advanced or metastatic disease that precludes curative surgical resection. [3]

The median age at diagnosis is 71 years, with peak incidence in the 7th and 8th decades. [4] Tumors arise most commonly in the pancreatic head (60-70%), followed by body/tail (20-25%), and diffuse involvement (10-15%). Head tumors typically present earlier due to biliary obstruction causing painless jaundice, while body/tail lesions remain clinically silent until they invade the celiac plexus or metastasize. [5]

Despite advances in surgical technique and systemic therapy, pancreatic cancer remains one of oncology's greatest challenges. The median survival for metastatic disease is 6-11 months, and even after successful R0 resection with adjuvant chemotherapy, 5-year survival reaches only 25-30%. [6,7] Emerging molecular insights into KRAS-driven oncogenesis and DNA damage repair deficiencies offer promise for targeted and immunotherapeutic approaches.

Key Facts

• Courvoisier's Law: In the presence of painless obstructive jaundice, a palpable non-tender gallbladder suggests malignancy (periampullary cancer or head of pancreas) rather than choledocholithiasis. Gallstones cause chronic inflammation and fibrosis, resulting in a contracted, non-distensible gallbladder. [8]

• Diabetes as a Harbinger: New-onset diabetes mellitus in adults over 50 years, particularly in non-obese individuals, warrants evaluation for pancreatic malignancy. Approximately 50% of pancreatic cancer patients develop diabetes within 2 years of diagnosis, and 1-2% of new-onset diabetics over 50 will be diagnosed with pancreatic cancer within 3 years. [9,10]

• Double Duct Sign: Concurrent dilatation of the common bile duct (CBD > 6mm) and main pancreatic duct (MPD > 3mm) on cross-sectional imaging is highly suggestive of a pancreatic head or periampullary mass causing dual obstruction. [11]

• CA 19-9 and Lewis Antigen: Carbohydrate antigen 19-9 (CA 19-9) is the most widely used serum biomarker, with sensitivity of 79-81% and specificity of 82-90% for pancreatic cancer. However, approximately 5-10% of the population are Lewis antigen-negative (Le^a-b-) and cannot synthesize CA 19-9, resulting in false-negative results even with extensive disease. [12,13]

Clinical Pearls

The Silent Tail Phenomenon: Pancreatic body and tail tumors lack early warning signs. Without proximity to the bile duct, they grow asymptomatically until they achieve substantial size, invade the celiac plexus (causing intractable epigastric/back pain), or metastasize to liver or peritoneum. At diagnosis, over 90% of body/tail tumors are unresectable, compared to 75-80% of head tumors. [14]

Depression as a Paraneoplastic Harbinger: Up to 50% of pancreatic cancer patients report clinically significant depression preceding diagnosis by 6-12 months, a rate substantially higher than other GI malignancies. The mechanism remains unclear but may involve cytokine-mediated effects or early metabolic derangements. [15]

Trousseau's Original Observation: Armand Trousseau described migratory thrombophlebitis in 1865 and later died from the very pancreatic cancer he had diagnosed in himself. Trousseau's syndrome (cancer-associated thrombosis) occurs in 10-20% of pancreatic cancer patients and may precede diagnosis by months. Mucin-producing adenocarcinomas activate coagulation cascades through tissue factor expression. [16]

CA 19-9 Kinetics in Treatment Monitoring: While CA 19-9 lacks sufficient sensitivity/specificity for screening, serial measurements provide valuable prognostic information. A > 50% decline in CA 19-9 after chemotherapy correlates with improved progression-free and overall survival. Levels > 1000 U/mL virtually confirm malignancy in the appropriate clinical context. [17]

---

2. Epidemiology

Incidence and Prevalence

Pancreatic cancer accounts for approximately 3% of all cancers but 7% of cancer deaths in the United States. [1] The global incidence is rising, with approximately 495,000 new cases and 466,000 deaths annually worldwide. [2] Incidence rates are highest in developed nations (10-12 per 100,000 in North America and Europe) and lowest in South-Central Asia and Africa (2-3 per 100,000). [18]

The lifetime risk of developing pancreatic cancer is approximately 1 in 64 (1.6%), with male predominance (male:female ratio 1.3:1). [4] Incidence increases dramatically with age, with median age at diagnosis of 71 years and 90% of cases occurring after age 55. [4]

Demographics

• Age: Rare before 40 years (less than 5% of cases). Incidence rises sharply after 50, peaking in the 7th-8th decades
• Sex: Slightly higher in males (age-adjusted incidence 13.0 vs 10.2 per 100,000)
• Race/Ethnicity: Highest rates in African Americans (15.4 per 100,000), followed by non-Hispanic whites (11.8), Hispanics (10.8), and Asian/Pacific Islanders (9.6) [19]
• Geography: Highest in Western/Northern Europe, North America, Australia/New Zealand; lowest in sub-Saharan Africa and South Asia

Risk Factors

Non-Modifiable Risk Factors

1. Age: Most powerful risk factor. Incidence less than 40 years is less than 2 per 100,000; rises to 100+ per 100,000 after age 80 [4]

2. Hereditary Syndromes (5-10% of cases): [20]

   • BRCA1/2 mutations: 3-6 fold increased risk. BRCA2 carriers have 3.5-10% lifetime risk
   • Lynch Syndrome (HNPCC): 4-11 fold increased risk
   • Peutz-Jeghers Syndrome (STK11): 132-fold increased risk; 11-36% lifetime risk
   • Familial Atypical Multiple Mole Melanoma (FAMMM, CDKN2A/p16): 13-39 fold increased risk
   • Hereditary Pancreatitis (PRSS1, SPINK1): 50-87 fold increased risk; 40% lifetime risk
   • Familial Pancreatic Cancer: First-degree relative affected confers 2-3 fold risk; two or more affected relatives increases risk 6-32 fold

3. ABO Blood Group: Non-O blood groups (A, B, AB) associated with modest increased risk (OR 1.3-1.5) compared to group O [21]

Modifiable Risk Factors

1. Smoking: Single most important modifiable risk factor. Current smokers have 2-3 fold increased risk (dose-dependent); risk declines after cessation, approaching baseline after 10-15 years. Smoking accounts for 20-25% of pancreatic cancers. [22]

2. Obesity: BMI > 30 kg/m² associated with 1.5-2 fold increased risk. Central adiposity (waist-to-hip ratio) appears more important than BMI. Obesity may account for 10-15% of cases. [23]

3. Diabetes Mellitus: Long-standing diabetes (> 5 years) modestly increases risk (RR 1.5-2.0). However, new-onset diabetes may be a consequence rather than cause of pancreatic cancer in many cases (see bidirectional relationship below). [9,10]

4. Chronic Pancreatitis: Increases risk 13-16 fold. Hereditary pancreatitis carries particularly high risk (40-55% lifetime risk). Alcohol-related chronic pancreatitis also elevates risk, though difficult to separate from direct alcohol effects. [24]

5. Alcohol: Heavy alcohol consumption (> 3 drinks/day) associated with modest increased risk (RR 1.2-1.5), likely mediated through chronic pancreatitis. Light-moderate consumption not clearly associated. [25]

6. Diet: Limited evidence; possible associations with high red/processed meat intake and low fruit/vegetable consumption. High folate intake may be protective. [26]

Protective Factors

• Physical activity: Regular exercise associated with 20-30% risk reduction
• Aspirin/NSAIDs: Regular use associated with modest risk reduction (RR 0.7-0.8) in some studies, though data inconsistent [27]

Diabetes-Pancreatic Cancer Relationship

The relationship between diabetes and pancreatic cancer is complex and bidirectional:

• Long-standing diabetes (> 5 years): Modest causal risk factor (RR 1.5-2.0)
• New-onset diabetes (less than 2 years): Often a consequence of pancreatic cancer. Tumor-secreted factors (adrenomedullin, S100A8) induce peripheral insulin resistance and beta-cell dysfunction. [9,10]
• Post-diagnosis diabetes resolution: In patients with new-onset diabetes who undergo successful tumor resection, 40-50% experience diabetes remission, supporting tumor-induced mechanism

---

3. Pathophysiology

Anatomical Considerations

The pancreas is a retroperitoneal organ measuring 12-20 cm in length, divided into head (with uncinate process), neck, body, and tail.

Head of Pancreas (60-70% of tumors):

• Lies within the C-loop of the duodenum
• Intimately related to superior mesenteric vessels (SMV, SMA), portal vein
• Contains the common bile duct and pancreatic duct (Duct of Wirsung), which converge at the Ampulla of Vater
• Tumors cause:
  • Biliary obstruction → Painless jaundice (earliest symptom in 70-80% of head tumors)
  • Duodenal obstruction → Gastric outlet obstruction (late complication, 10-20%)
  • Double duct sign → Concurrent CBD and MPD dilatation

Body and Tail (20-25% of tumors):

• Extends from neck to splenic hilum
• Related posteriorly to celiac trunk, splenic artery/vein, left kidney/adrenal
• Anterior to aorta and inferior vena cava at level of L1-L2
• Tumors cause:
  • Celiac plexus invasion → Severe epigastric pain radiating to back
  • Splenic vein thrombosis → Left-sided portal hypertension (gastric varices, splenomegaly)
  • Late presentation → 90% unresectable at diagnosis

The retroperitoneal location and lack of a sensory capsule explain delayed symptom onset. Tumors can grow to several centimeters before producing mass effect or invading adjacent structures.

Molecular Pathogenesis

Pancreatic cancer develops through progressive accumulation of genetic alterations, evolving from precursor lesions (Pancreatic Intraepithelial Neoplasia, PanIN) to invasive carcinoma over 10-15 years. [28]

Driver Mutations (in order of frequency)

1. KRAS (90-95%): Gain-of-function mutations (predominantly codon 12) activate RAS/MAPK and PI3K/AKT pathways, driving proliferation, survival, and metabolic reprogramming. KRAS G12D and G12V are most common variants. KRAS mutations are early events (present in PanIN-1A) and considered initiating events. [28,29]

2. TP53 (50-75%): Loss-of-function mutations or deletions abrogate cell cycle checkpoints and apoptotic responses to DNA damage. TP53 alterations occur later (PanIN-3/carcinoma in situ stage) and correlate with progression to invasive disease. [28]

3. CDKN2A/p16 (90%): Homozygous deletion or promoter methylation silences this tumor suppressor, permitting unregulated cell cycle progression (loss of G1/S checkpoint). Present in PanIN-2 lesions. [28]

4. SMAD4/DPC4 (55%): Loss results in impaired TGF-β signaling and loss of growth inhibitory signals. SMAD4 loss is associated with more aggressive disease and worse prognosis. [30]

Emerging Genomic Subtypes

Transcriptomic profiling identifies distinct molecular subtypes with therapeutic implications:

• Classical subtype (40%): High expression of adhesion genes; better prognosis; responsive to FOLFIRINOX
• Basal-like/Squamous subtype (25%): TP53/KDM6A mutations; poor prognosis; resistant to chemotherapy; enriched for mesenchymal and inflammatory markers
• Aberrantly Differentiated Endocrine Exocrine (ADEX) (15%): Upregulation of endocrine genes
• Immunogenic subtype (rare): High tumor mutational burden; potential immunotherapy responsiveness [31]

DNA Damage Repair Deficiencies (5-10% of cases)

• BRCA1/2: Germline or somatic mutations in 4-7% of cases. Confer sensitivity to platinum chemotherapy and PARP inhibitors. [32]
• Mismatch Repair Deficiency/Microsatellite Instability-High (MMR-d/MSI-H): Present in 1-2% of cases, primarily Lynch syndrome-associated. High tumor mutational burden predicts response to immune checkpoint inhibitors. [33]
• ATM, PALB2, RAD51C: Additional homologous recombination deficiency genes present in 2-3%

Tumor Microenvironment

Pancreatic cancer is characterized by profound desmoplasia (dense stromal reaction), comprising up to 90% of tumor volume. The stroma consists of:

• Cancer-Associated Fibroblasts (CAFs): Secrete extracellular matrix proteins (collagen, fibronectin), growth factors, and cytokines
• Immunosuppressive cells: Myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs)
• Hypovascular stroma: Dense collagen matrix compresses blood vessels, creating hypoxic environment and impairing drug delivery [34]

This stromal fortress provides mechanical barrier to drug penetration, promotes immune evasion, and contributes to therapeutic resistance.

Metastatic Patterns

Pancreatic cancer metastasizes via:

1. Lymphatic spread: Peripancreatic, celiac, superior mesenteric, para-aortic nodes (30-40% at diagnosis)
2. Hematogenous dissemination: Liver (most common, 50-70% of metastatic cases), lungs (20-30%), peritoneum (20-30%)
3. Perineural invasion: Present in > 90% of cases; correlates with pain and local recurrence [35]
4. Direct extension: Into duodenum, stomach, colon, spleen, adrenal glands

---

4. Clinical Presentation

Symptoms by Tumor Location

Head of Pancreas Tumors

1. Painless Jaundice (70-80%): Progressive, painless obstructive jaundice is the hallmark presentation

   • Dark urine (conjugated bilirubinuria)
   • Pale/clay-colored stools (absence of stercobilin)
   • Pruritus (bile salt deposition in skin)
   • Onset typically when bilirubin > 50 μmol/L (3 mg/dL)

2. Weight Loss (70-80%): Multifactorial

   • Cancer cachexia (cytokine-mediated muscle wasting)
   • Anorexia
   • Pancreatic exocrine insufficiency (maldigestion)
   • Early satiety (duodenal compression)

3. Epigastric Pain (40-50%): Dull, gnawing pain radiating to back

   • Worse when supine (tumor compresses retroperitoneal structures)
   • Relieved by leaning forward/fetal position
   • Suggests local invasion or celiac plexus involvement

4. Steatorrhea (20-30%): Bulky, greasy, foul-smelling stools that float

   • Results from pancreatic enzyme deficiency (lipase, amylase, proteases)
   • Leads to fat-soluble vitamin deficiencies (A, D, E, K)

5. Gastric Outlet Obstruction (10-15%): Late complication

   • Persistent vomiting (undigested food)
   • Early satiety
   • Indicates duodenal compression/invasion

Body/Tail Tumors

1. Epigastric/Back Pain (80-90%): Typically the presenting symptom

   • Severe, unremitting pain
   • Indicates celiac plexus invasion or retroperitoneal extension
   • Often requires opioid analgesia

2. Weight Loss (80-90%): More pronounced than head tumors due to later presentation

3. New-Onset Diabetes (15-20%): Destruction of islet cells

   • May precede diagnosis by months to years
   • Typically in non-obese patient > 50 years

4. Splenomegaly (10-15%): Splenic vein thrombosis causing left-sided portal hypertension

5. Gastric Varices: Rare but characteristic complication of splenic vein thrombosis

Constitutional Symptoms

• Profound fatigue and malaise (60-70%)
• Anorexia (50-60%)
• Depression/anxiety (40-50%): May precede diagnosis by months [15]
• Fever (10-15%): Low-grade, typically indicates biliary sepsis or tumor necrosis

Paraneoplastic Syndromes

1. Trousseau's Syndrome (10-20%): Migratory thrombophlebitis or venous thromboembolism

   • Recurrent superficial thrombophlebitis affecting different sites
   • Deep vein thrombosis or pulmonary embolism
   • May precede cancer diagnosis by 6-12 months
   • Associated with mucin-producing adenocarcinomas [16]

2. Panniculitis (Rare, less than 1%): Subcutaneous fat necrosis

   • Tender, erythematous nodules on extremities or trunk
   • Histology: fat necrosis with "ghost cells"
   • Due to circulating pancreatic enzymes (lipase)

3. Polyarthritis (Rare): Non-erosive arthritis affecting small joints

---

5. Clinical Examination

General Inspection

• Cachexia: Severe muscle wasting, temporal wasting
• Jaundice: Scleral icterus (earliest sign), generalized yellow discoloration
• Excoriation marks: Linear scratch marks from pruritus
• Pallor: Anemia from chronic disease or occult GI bleeding

Abdominal Examination

Inspection

• Visible jaundice
• Abdominal distension (ascites if peritoneal carcinomatosis)

Palpation

1. Courvoisier's Sign: Palpable, non-tender gallbladder in the presence of painless jaundice

   • Suggests malignant biliary obstruction (head of pancreas, cholangiocarcinoma, ampullary carcinoma)
   • Gallbladder palpable in only 25-30% of cases (not sensitive but highly specific) [8]

2. Epigastric Mass: Palpable pancreatic mass (20-30% of cases)

   • Fixed, firm, irregular mass
   • Indicates advanced, unresectable disease

3. Hepatomegaly: Nodular liver suggests metastatic disease (40-50% at presentation)

4. Ascites: Shifting dullness; indicates peritoneal carcinomatosis (poor prognosis)

5. Splenomegaly: Suggests splenic vein thrombosis (body/tail tumors)

Percussion and Auscultation

• Ascites: Shifting dullness, fluid thrill
• Bowel sounds: May be high-pitched/tinkling if gastric outlet obstruction

Lymphadenopathy

1. Virchow's Node (Troisier's Sign): Palpable left supraclavicular lymph node

   • Indicates metastatic spread via thoracic duct
   • Named after French pathologist Charles-Emile Troisier
   • Present in 5-10% of cases

2. Sister Mary Joseph's Nodule: Periumbilical nodule

   • Metastatic deposit to umbilicus via hematogenous spread
   • Named after Sister Mary Joseph Dempsey (surgical assistant to William Mayo)
   • Rare (less than 2%) but indicates stage IV disease

Lower Extremity Examination

• Peripheral edema: Hypoalbuminemia (malnutrition, liver dysfunction)
• Deep vein thrombosis: Unilateral limb swelling, warmth, tenderness (Trousseau's syndrome)
• Migratory thrombophlebitis: Tender, cord-like superficial veins at varying locations

---

6. Investigations

Laboratory Studies

Liver Function Tests

Classic Obstructive Pattern:

• Bilirubin: Markedly elevated (typically > 100 μmol/L or 6 mg/dL). Predominantly conjugated (direct) hyperbilirubinemia
• Alkaline Phosphatase (ALP): Significantly elevated (3-10x upper limit of normal)
• Gamma-Glutamyl Transferase (GGT): Elevated (parallels ALP)
• Transaminases (AST/ALT): Mildly elevated (1-3x ULN); disproportionate elevation suggests hepatocellular injury (cholangitis, metastases)
• Albumin: May be low (malnutrition, chronic disease)
• Prothrombin Time (PT/INR): Prolonged (vitamin K malabsorption from cholestasis)

Tumor Markers

1. CA 19-9 (Carbohydrate Antigen 19-9) [12,13,17]:

   • Sensitivity: 79-81% at cutoff of 37 U/mL
   • Specificity: 82-90% (false positives in benign biliary obstruction, cholangitis, chronic pancreatitis)
   • Clinical Use:
     • NOT recommended for screening (low positive predictive value in asymptomatic population)
     • Useful for prognosis: Levels > 1000 U/mL highly suggestive of unresectable disease
     • Monitoring treatment response: > 50% decline correlates with improved survival
   • Limitations:
     • Lewis antigen-negative individuals (Le^a-b-, 5-10% of population) cannot synthesize CA 19-9 → false negatives
     • Elevated in benign conditions: cholestasis (can normalize after biliary drainage), pancreatitis, cirrhosis
     • Not useful for early detection (normal in many early-stage cases)

2. CEA (Carcinoembryonic Antigen): Less sensitive/specific; may be elevated in 40-50% of cases. Combined with CA 19-9 may improve diagnostic accuracy.

Complete Blood Count

• Anemia: Normocytic normochromic (chronic disease) or microcytic (occult GI bleeding)
• Thrombocytosis: Paraneoplastic phenomenon (20-30%)
• Leukocytosis: If cholangitis complicating biliary obstruction

Metabolic Panel

• Glucose: Elevated in new-onset diabetes (15-20% of cases) [9,10]
• Creatinine: Monitor renal function (important for chemotherapy eligibility)

Imaging Studies

CT Pancreas Protocol (Triple-Phase CT)

Gold Standard for Diagnosis and Resectability Assessment [36]

Technique:

• Non-contrast phase: Identify calcifications, hemorrhage
• Arterial phase (25-30 seconds post-contrast): Pancreatic parenchyma enhances maximally; tumors appear hypodense (hypovascular)
• Portal venous phase (60-70 seconds): Assess liver metastases, vascular involvement
• Delayed phase (optional): Further characterize indeterminate lesions

Imaging Features:

• Primary tumor: Hypodense mass relative to normal pancreas (pancreas enhances, tumor does not)
• Pancreatic duct dilatation: Abrupt caliber change ("duct cut-off sign")
• Bile duct dilatation: Double duct sign (CBD > 6mm + MPD > 3mm)
• Vascular involvement: Key determinant of resectability
  • "Superior Mesenteric Artery (SMA): Assess circumferential involvement"
  • "Superior Mesenteric Vein/Portal Vein (SMV/PV): Assess thrombosis, narrowing, encasement"
  • "Celiac axis, hepatic artery: Assess involvement"
• Metastases: Liver, lungs, peritoneum, lymph nodes
• Pancreatic atrophy: Upstream gland atrophy distal to obstructing tumor

Resectability Classification (NCCN Criteria) [36]:

1. Resectable:

   • No arterial involvement (SMA, celiac, hepatic artery)
   • No SMV/PV involvement OR ≤180° involvement without vein occlusion

2. Borderline Resectable:

   • SMA involvement ≤180°
   • SMV/PV involvement > 180° OR ≤180° with contour irregularity/thrombosis but reconstructable
   • Gastroduodenal artery encasement up to hepatic artery

3. Locally Advanced (Unresectable):

   • SMA or celiac axis involvement > 180°
   • SMV/PV occlusion not amenable to reconstruction
   • Aortic involvement

4. Metastatic: Distant metastases present

Sensitivity/Specificity: 85-90% for detecting pancreatic masses; 70-85% for resectability determination

MRI/MRCP (Magnetic Resonance Cholangiopancreatography)

Indications:

• CT contraindicated (contrast allergy, renal impairment)
• Characterize cystic lesions (IPMN vs mucinous cystic neoplasm)
• Better soft tissue contrast for small tumors (less than 2cm)
• Delineate pancreatic/bile duct anatomy without invasive ERCP

Advantages over CT:

• Superior contrast resolution for liver metastases
• No ionizing radiation
• Non-invasive biliary/pancreatic duct visualization

Limitations:

• Longer acquisition time (motion artifact if patient unable to cooperate)
• Less available than CT
• Inferior spatial resolution for small vessels

Endoscopic Ultrasound (EUS)

Most Sensitive Imaging Modality for Small Tumors [37]

Indications:

• High clinical suspicion with negative/equivocal CT
• Tumor less than 2cm (sensitivity 93-100% vs 70-85% for CT)
• Tissue diagnosis via fine-needle aspiration/biopsy (FNA/FNB)
• Assessment of T-stage and regional lymph nodes

Diagnostic Accuracy:

• Sensitivity 95-100% for detecting pancreatic masses
• Accuracy 80-85% for T-staging
• Accuracy 60-70% for N-staging (limited by inability to differentiate reactive vs malignant nodes)

EUS-Guided FNA/FNB:

• Cytologic yield: 80-95% with experienced cytopathologist
• Indications for tissue diagnosis:
  • Borderline resectable/locally advanced disease (confirm before neoadjuvant therapy)
  • Metastatic disease (confirm before palliative chemotherapy)
  • Atypical presentation or imaging
• NOT routinely performed in clearly resectable disease (risk of tumor seeding, delay to surgery)

Contraindications: Coagulopathy, severe thrombocytopenia, intervening gastric varices

Positron Emission Tomography (PET-CT)

Limited Role in Primary Diagnosis

Advantages:

• Detects occult metastases in 10-15% of cases deemed resectable by CT
• Useful for restaging after neoadjuvant therapy

Limitations:

• False positives: Pancreatitis, autoimmune pancreatitis
• False negatives: Small tumors (less than 1cm), mucinous tumors (low FDG avidity)
• Not superior to high-quality pancreas protocol CT for resectability assessment

Current Recommendations: Not routinely recommended; consider in select cases to rule out distant disease before surgery

Chest X-Ray or Chest CT

• Purpose: Detect pulmonary metastases
• Chest CT recommended if surgery contemplated (more sensitive than CXR)

ERCP (Endoscopic Retrograde Cholangiopancreatography)

No Longer a Diagnostic Tool (replaced by MRCP/EUS)

Current Indications:

• Therapeutic biliary decompression: Stent placement for jaundice relief in unresectable disease
• Brush cytology if diagnosis uncertain (sensitivity 30-60%, low yield)

Complications: Pancreatitis (3-5%), bleeding, perforation, cholangitis

Histopathological Confirmation

When to Obtain Tissue Diagnosis

1. Borderline resectable or locally advanced disease: Confirm before neoadjuvant chemotherapy
2. Metastatic disease: Confirm before palliative systemic therapy
3. Atypical presentation: Rule out alternative diagnoses (lymphoma, metastasis from other primary, autoimmune pancreatitis)

When NOT to Obtain Tissue

• Clearly resectable disease with typical clinical/imaging features: Proceed directly to surgery (avoid delay and risk of tumor seeding)

Techniques

1. EUS-FNA/FNB: Preferred method (highest yield, lowest complication rate)
2. Percutaneous CT-guided biopsy: If EUS unavailable or tumor inaccessible by EUS
3. Surgical biopsy: At time of laparotomy/laparoscopy if unresectable

Histopathological Types

• Pancreatic Ductal Adenocarcinoma (PDAC): 85-90%
• Variants: Adenosquamous (4%), colloid (2%), hepatoid (less than 1%)
• Other: Acinar cell carcinoma (1-2%), pancreatic neuroendocrine tumors (PNETs, 5%), solid pseudopapillary neoplasm (less than 1%)

Staging

TNM Staging (AJCC 8th Edition):

• T1: Tumor ≤2cm (T1a ≤0.5cm, T1b 0.5-1cm, T1c 1-2cm)
• T2: Tumor > 2cm and ≤4cm
• T3: Tumor > 4cm
• T4: Tumor involves celiac axis, SMA, or common hepatic artery (unresectable)
• N0/N1/N2: Based on number of positive lymph nodes (0 / 1-3 / ≥4)
• M0/M1: Absence or presence of distant metastases

Stage Groupings:

• Stage IA: T1 N0 M0
• Stage IB: T2 N0 M0
• Stage IIA: T3 N0 M0
• Stage IIB: T1-3 N1 M0
• Stage III: T1-3 N2 M0 OR T4 Any N M0
• Stage IV: Any T Any N M1

---

7. Management

Multidisciplinary Team Approach

All pancreatic cancer cases should be discussed at a specialist HPB (Hepato-Pancreato-Biliary) multidisciplinary team meeting including:

• HPB surgeon
• Medical oncologist
• Radiation oncologist
• Gastroenterologist
• Interventional radiologist
• Histopathologist
• Specialist nurse
• Palliative care physician

Management Algorithm by Resectability Status

          SUSPECTED PANCREATIC CANCER
         (Jaundice / Weight Loss / Pain)
                      ↓
              CT PANCREAS PROTOCOL
                      ↓
        ┌─────────────┼─────────────┐
    RESECTABLE    BORDERLINE    LOCALLY ADVANCED
    (15-20%)     RESECTABLE         OR
        ↓          (10-15%)      METASTATIC
        ↓              ↓          (65-75%)
        ↓              ↓              ↓
    Surgery ←    Neoadjuvant   Systemic Therapy
     (R0/R1      Therapy       (Palliative Intent)
   resection)    (FOLFIRINOX      ↓
        ↓        or Gem/Abrax)  Symptom Control:
        ↓              ↓        - Biliary stent
   Adjuvant         Restage     - Enzyme replacement
   Chemotherapy      CT         - Pain management
   (6 months)         ↓         - Nutrition support
                 If converted
                 to resectable
                      ↓
                   Surgery

1. Surgical Management (Curative Intent)

Eligibility: Only 15-20% of patients present with resectable disease [3,7]

Preoperative Optimization:

• Nutritional support (dietitian, consider enteral feeding if severe malnutrition)
• Correction of coagulopathy (vitamin K supplementation if obstructive jaundice)
• Biliary drainage (controversial; may increase perioperative complications but necessary if severe cholestasis with coagulopathy or cholangitis)
• Smoking cessation
• Dental clearance (reduce infection risk)

Pancreatoduodenectomy (Whipple's Procedure)

Indication: Tumors of pancreatic head, uncinate process, ampulla, distal CBD

Resected Structures:

• Pancreatic head and uncinate process
• Duodenum (all four parts)
• Distal common bile duct
• Gallbladder
• ± Distal stomach (classical Whipple) vs pylorus preservation (PPPD)
• Regional lymph nodes (peripancreatic, hepatoduodenal, celiac, superior mesenteric)

Reconstruction (3 anastomoses):

1. Pancreaticojejunostomy: Pancreatic remnant to jejunum (highest risk of leak)
2. Hepaticojejunostomy: Bile duct to jejunum
3. Gastrojejunostomy (or duodenojejunostomy if pylorus-preserving)

Operative Time: 5-8 hours

Pylorus-Preserving vs Classical:

• PPPD associated with better nutritional outcomes and less dumping syndrome
• No difference in oncological outcomes (5-year survival, margin status)
• PPPD may have higher rates of delayed gastric emptying (15-30% vs 10-20%)

Perioperative Outcomes:

• Mortality: less than 5% in high-volume centers (> 20 cases/year); up to 15-20% in low-volume centers [38]
• Morbidity: 40-50%
  • "Pancreatic fistula (15-25%): Most common complication. Defined as drain fluid amylase > 3x serum on POD 3. Grade B/C fistulas require intervention"
  • "Delayed gastric emptying (15-30%): Inability to tolerate diet, prolonged nasogastric drainage"
  • "Post-pancreatectomy hemorrhage (5-10%): Early (intraoperative) or late (erosion into vessels from fistula)"
  • Bile leak (2-5%)
  • Wound infection (10-15%)
  • Intra-abdominal abscess (5-10%)

Hospital Stay: 7-14 days (longer if complications)

Distal Pancreatectomy ± Splenectomy

Indication: Tumors of pancreatic body/tail

Resected Structures:

• Pancreatic body and tail
• Spleen (in most cases; spleen-preserving possible in select benign cases but not oncologically appropriate for cancer)
• Regional lymph nodes

Perioperative Outcomes:

• Mortality: less than 2%
• Morbidity: 30-40%
  • "Pancreatic fistula (20-30%): More common than Whipple (larger cut surface)"
  • "Splenic complications (if spleen preserved): Infarction, thrombosis"
  • "Post-splenectomy sepsis: Requires lifelong antibiotic prophylaxis and vaccinations (pneumococcus, meningococcus, Haemophilus)"

Total Pancreatectomy

Indication: Multifocal disease, extensive tumor involvement, uncontrollable pancreatic fistula after partial resection

Consequences:

• Brittle diabetes: Requires lifelong insulin (loss of both alpha and beta cells → no glucagon counterregulation)
• Pancreatic exocrine insufficiency: Lifelong enzyme replacement
• Quality of life: Significantly impacted; reserved for select cases

Margin Status and Resection Quality

• R0 (Negative Margins): No tumor at resection margin (ideally > 1mm clearance). Achieved in 60-80% of resections. Associated with improved survival (median 25-30 months vs 12-18 months for R1) [39]
• R1 (Microscopic Positive Margin): Tumor at or within 1mm of margin. Associated with higher local recurrence rates
• R2 (Macroscopic Residual): Gross tumor left behind (should be avoided; consider unresectable)

Volume-Outcome Relationship: Strong evidence that high-volume centers (> 20 pancreatic resections/year) have:

• Lower perioperative mortality (2-4% vs 10-15% in low-volume centers) [38]
• Higher R0 resection rates
• Better long-term survival
• Recommendation: Refer to specialized HPB centers

2. Neoadjuvant Therapy

Indications:

1. Borderline Resectable Disease: Improve likelihood of R0 resection
2. High-Risk Resectable Disease: CA 19-9 > 500, large primary, extensive lymphadenopathy (controversial)

Regimens:

• FOLFIRINOX (2-4 months): Most commonly used in fit patients
• Gemcitabine/Nab-Paclitaxel (2-4 months): Alternative in less fit patients
• Chemoradiotherapy: Role controversial; some centers use after initial chemotherapy

Goals:

• Downstage tumor to allow R0 resection
• Treat micrometastatic disease early
• Select patients with favorable biology (those who progress rapidly are spared futile surgery)

Evidence:

• Retrospective data suggest improved R0 rates (60-80% vs 40-60%)
• Survival benefit not definitively proven in randomized trials (RCTs ongoing)
• Increasingly adopted as standard approach for borderline resectable disease [40]

3. Adjuvant Chemotherapy (Post-Operative)

Indication: ALL patients with resected pancreatic cancer (even R0 resection has high recurrence risk)

Timing: Initiate within 8-12 weeks of surgery (once adequately recovered)

Regimens:

1. Modified FOLFIRINOX (mFOLFIRINOX): Current Standard of Care [41]

   • PRODIGE 24/CCTG PA.6 Trial (2018): mFOLFIRINOX vs gemcitabine
   • Median disease-free survival: 21.6 vs 12.8 months (HR 0.58)
   • Median overall survival: 54.4 vs 35.0 months (HR 0.64)
   • Toxicity: Grade 3-4 in 75% (neutropenia, diarrhea, neuropathy, fatigue)
   • Eligibility: ECOG PS 0-1, adequate organ function, age less than 75 years (relative)

2. Gemcitabine + Capecitabine: Alternative for less fit patients [42]

   • ESPAC-4 Trial (2017): Gem/Cap vs gemcitabine alone
   • Median overall survival: 28.0 vs 25.5 months (HR 0.82, p=0.032)
   • Toxicity: Better tolerated than FOLFIRINOX

3. Gemcitabine Monotherapy: For frail/elderly patients unable to tolerate combination therapy

Duration: 6 months (24 weeks)

Compliance: Only 50-60% of patients complete planned adjuvant therapy due to surgical complications, delayed recovery, or disease recurrence

4. Palliative Systemic Therapy (Metastatic/Unresectable Disease)

Goal: Prolong survival, maintain quality of life, control symptoms

First-Line Therapy

1. FOLFIRINOX (Fit Patients, ECOG PS 0-1) [43]

• Regimen: Oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², 5-FU bolus 400 mg/m² + infusion 2400 mg/m² over 46 hours. Every 2 weeks.
• PRODIGE/ACCORD 11 Trial (2011): FOLFIRINOX vs gemcitabine
  • "Median overall survival: 11.1 vs 6.8 months (HR 0.57, pless than 0.001)"
  • "Median progression-free survival: 6.4 vs 3.3 months"
  • "Objective response rate: 31.6% vs 9.4%"
• Toxicity: Grade 3-4 in 45% (neutropenia, diarrhea, peripheral neuropathy, fatigue)
• Requirements: Age less than 75 years (relative), bilirubin less than 1.5x ULN, adequate bone marrow/renal/hepatic function

2. Gemcitabine + Nab-Paclitaxel (Fit to Moderate Fitness, ECOG PS 0-2) [44]

• Regimen: Gemcitabine 1000 mg/m² + nab-paclitaxel 125 mg/m². Days 1, 8, 15 of 28-day cycle.
• MPACT Trial (2013): Gem/Nab vs gemcitabine alone
  • "Median overall survival: 8.5 vs 6.7 months (HR 0.72, pless than 0.001)"
  • "Median progression-free survival: 5.5 vs 3.7 months"
  • "Objective response rate: 23% vs 7%"
• Toxicity: Neutropenia, peripheral neuropathy, fatigue

3. Gemcitabine Monotherapy: For ECOG PS 2-3 or comorbidities precluding combination therapy

• Median overall survival: 6-7 months
• Better tolerated, palliative benefit

Choice of First-Line:

• FOLFIRINOX: Most effective; for fit patients willing to accept toxicity
• Gem/Nab: Intermediate efficacy/toxicity; broader patient eligibility
• No head-to-head comparison; choice based on patient fitness, preferences, comorbidities

Second-Line Therapy

• After FOLFIRINOX: Gemcitabine-based (Gem/Nab or Gem monotherapy)
• After Gemcitabine: 5-FU/leucovorin or OFF (oxaliplatin/5-FU/leucovorin)
• Median survival from second-line: 4-6 months

Targeted Therapies

1. PARP Inhibitors (BRCA1/2 or PALB2 Germline Mutations):

• Olaparib: [45]
  • "POLO Trial (2019): Olaparib vs placebo as maintenance after platinum-based first-line (in germline BRCA-mutated patients)"
  • "Median progression-free survival: 7.4 vs 3.8 months (HR 0.53)"
  • FDA-approved as maintenance in germline BRCA-mutated metastatic pancreatic cancer with stable disease/response after ≥16 weeks of platinum chemotherapy
• Testing: ALL pancreatic cancer patients should undergo germline genetic testing (4-7% have BRCA1/2 mutations) [32]

2. Immune Checkpoint Inhibitors (MSI-H/dMMR or TMB-High):

• Pembrolizumab: FDA-approved for MSI-H/dMMR solid tumors (tumor-agnostic approval)
• Rare in pancreatic cancer (1-2% are MSI-H) [33]
• Response rates 40-60% in MSI-H pancreatic cancer

3. Other Targeted Therapies: KRAS G12C inhibitors (sotorasib, adagrasib) under investigation; only 1-2% of pancreatic cancers harbor G12C mutation (most are G12D/G12V)

5. Radiation Therapy

Role: Limited and controversial in pancreatic cancer

Potential Indications:

1. Neoadjuvant chemoradiation: Borderline resectable disease (select centers; not standard)
2. Adjuvant chemoradiation: Not routinely recommended after R0 resection (no survival benefit in ESPAC-1 trial)
3. Locally advanced unresectable: Consolidation after induction chemotherapy in select cases
4. Palliative: Pain control for locally symptomatic disease

Techniques:

• Conventional external beam radiotherapy (50.4 Gy in 28 fractions)
• Stereotactic body radiotherapy (SBRT): Higher doses in fewer fractions (5 fractions)

Toxicity: Nausea, diarrhea, fatigue, duodenal ulceration, bleeding

6. Palliative and Supportive Care

Biliary Obstruction

Endoscopic Biliary Stenting (ERCP): [46]

• Metal stents: Preferred for survival > 3 months (lower reocclusion rate, longer patency)
• Plastic stents: For short-term palliation or if metal stent not available
• Success rate: 90-95%
• Complications: Pancreatitis (3-5%), cholangitis (5-10%), stent occlusion (15-30% at 6 months)
• Effect: Relieves jaundice and pruritus; improves quality of life

Percutaneous Transhepatic Biliary Drainage (PTBD): If ERCP fails or inaccessible anatomy

Surgical Bypass (Hepaticojejunostomy): Rarely performed; reserved for fit patients with long life expectancy and failed endoscopic approaches

Gastric Outlet Obstruction (GOO)

• Endoscopic duodenal stenting: First-line; success rate 85-90%; faster recovery than surgery
• Surgical gastrojejunostomy: More durable; consider if laparotomy performed for other reasons or endoscopic stenting fails

Pancreatic Exocrine Insufficiency

Pancreatic Enzyme Replacement Therapy (PERT): [47]

• Indication: ALL pancreatic cancer patients (tumor obstructs pancreatic duct → enzyme deficiency)
• Regimen: Creon (pancrelipase) 25,000-50,000 units lipase with each meal; 10,000-25,000 units with snacks
• Titrate to control steatorrhea
• Benefits: Improves nutritional status, reduces weight loss, improves quality of life
• Adjunct: Proton pump inhibitor (omeprazole 20-40mg daily) increases enzyme activity by reducing gastric acid degradation

Pain Management

1. Pharmacological:

   • WHO Analgesic Ladder: Paracetamol → NSAIDs → weak opioids (codeine, tramadol) → strong opioids (morphine, oxycodone, fentanyl)
   • Adjuvants: Pregabalin/gabapentin for neuropathic pain; dexamethasone for inflammation

2. Celiac Plexus Block/Neurolysis: [48]

   • Technique: EUS-guided or CT-guided injection of local anesthetic (block) or alcohol/phenol (neurolysis)
   • Efficacy: 70-90% experience significant pain reduction
   • Duration: 3-6 months
   • Indications: Severe pain refractory to opioids; reduce opioid requirements
   • Timing: Consider early (better efficacy before extensive retroperitoneal invasion)

3. Radiotherapy: Palliative radiation for painful local disease (25-30 Gy in 5-10 fractions)

Nutritional Support

• Dietitian referral: ALL patients
• Oral nutritional supplements: High-protein, high-calorie
• Enteral feeding: Nasojejunal or jejunostomy tube if severe dysphagia or gastric outlet obstruction
• Parenteral nutrition: Last resort if gut non-functional

Psychosocial Support

• Depression/anxiety screening: High prevalence (40-50%) [15]
• Antidepressants: SSRIs (sertraline, citalopram) first-line
• Psychological therapies: CBT, counseling
• Palliative care: Early integration (at diagnosis for metastatic disease) improves quality of life and may prolong survival [49]

Thromboprophylaxis

• Trousseau's syndrome (cancer-associated thrombosis) occurs in 10-20% [16]
• Prophylaxis: Consider LMWH (enoxaparin 40mg SC daily) in ambulatory patients with advanced disease
• Treatment: Therapeutic LMWH for VTE (superior to warfarin in cancer patients)

---

8. Complications

Disease-Related Complications

1. Biliary Sepsis (Cholangitis): Bacterial infection of obstructed biliary tree. Requires urgent antibiotics and biliary drainage.

2. Gastric Outlet Obstruction: 10-20% of head tumors. Causes intractable vomiting, dehydration, malnutrition.

3. Pancreatic Exocrine Insufficiency: Universal in advanced disease. Leads to malabsorption, steatorrhea, weight loss, fat-soluble vitamin deficiencies.

4. New-Onset Diabetes: 15-20% of cases. May be presenting feature (especially body/tail tumors).

5. Venous Thromboembolism: 10-20% incidence. Includes DVT, PE, Trousseau's syndrome (migratory thrombophlebitis).

6. Hemorrhage: Erosion into GI tract or major vessels (rare but life-threatening).

7. Peritoneal Carcinomatosis: Malignant ascites; poor prognosis (median survival 2-3 months).

Treatment-Related Complications

Post-Surgical

• Pancreatic fistula (15-30%)
• Delayed gastric emptying (15-30%)
• Post-pancreatectomy hemorrhage (5-10%)
• Intra-abdominal abscess (5-10%)
• Perioperative mortality (2-5% in high-volume centers)

Chemotherapy

• FOLFIRINOX: Neutropenic sepsis (5-10%), peripheral neuropathy (cumulative with oxaliplatin), diarrhea (15-20% grade 3-4)
• Gemcitabine/Nab-paclitaxel: Neutropenia, peripheral neuropathy, fatigue
• General: Nausea/vomiting, mucositis, alopecia, thrombocytopenia

---

9. Prognosis and Outcomes

Overall Survival

Pancreatic cancer has the worst prognosis of common malignancies:

• 5-year survival: 7-9% (all stages combined) [1,2]
• 10-year survival: less than 2%

Survival by Stage (SEER Data)

• Localized (confined to pancreas, 10% at diagnosis): 5-year survival 39%
• Regional (lymph node involvement or local invasion, 30%): 5-year survival 13%
• Distant metastases (60%): 5-year survival 3%

Resected Disease

• Median overall survival after R0 resection + adjuvant chemotherapy: 25-54 months (depending on regimen) [41,42]
• 5-year survival: 20-30%
• Recurrence rate: 70-80% within 2 years (distant > local)

Unresectable/Metastatic Disease

• Median survival with best supportive care: 3-6 months
• Median survival with FOLFIRINOX: 11.1 months [43]
• Median survival with Gem/Nab: 8.5 months [44]
• Median survival with gemcitabine monotherapy: 6-7 months

Prognostic Factors

Favorable:

• Resectable disease at presentation
• R0 resection with negative margins (> 1mm)
• Small tumor size (less than 2cm)
• Well-differentiated histology
• Absence of lymph node metastases
• Low CA 19-9 (less than 200 U/mL)
• Good performance status (ECOG 0-1)
• Completion of adjuvant chemotherapy
• BRCA1/2 mutation (responds to platinum/PARP inhibitors)
• MSI-H/dMMR status (responds to immunotherapy)

Unfavorable:

• Locally advanced or metastatic disease
• R1/R2 resection
• Poor tumor differentiation

• 4 positive lymph nodes

• Elevated CA 19-9 (> 1000 U/mL)
• Poor performance status (ECOG 2-3)
• Significant weight loss (> 10% body weight)
• SMAD4 loss (associated with aggressive disease)
• Basal-like/squamous molecular subtype

Recurrence Patterns After Resection

• Local recurrence: 20-30%
• Distant recurrence: 50-60% (liver most common, then lungs, peritoneum)
• Both local and distant: 10-20%
• Median time to recurrence: 12-18 months

---

10. Evidence and Guidelines

Key Guidelines

Landmark Trials

1. PRODIGE 24 / CCTG PA.6 (2018) - Adjuvant mFOLFIRINOX [41]

• Question: Is mFOLFIRINOX superior to gemcitabine after resection?
• Population: 493 patients with resected pancreatic cancer
• Results:
  • "Median disease-free survival: 21.6 vs 12.8 months (HR 0.58, pless than 0.001)"
  • "Median overall survival: 54.4 vs 35.0 months (HR 0.64, p=0.003)"
• Impact: Established mFOLFIRINOX as new standard adjuvant therapy for fit patients

2. ESPAC-4 (2017) - Adjuvant Gemcitabine + Capecitabine [42]

• Question: Is Gem/Cap superior to gemcitabine monotherapy after resection?
• Population: 732 patients with resected pancreatic cancer
• Results:
  • "Median overall survival: 28.0 vs 25.5 months (HR 0.82, p=0.032)"
• Impact: Established Gem/Cap as alternative adjuvant regimen (better tolerated than FOLFIRINOX)

3. PRODIGE 4 / ACCORD 11 (2011) - Palliative FOLFIRINOX [43]

• Question: Is FOLFIRINOX superior to gemcitabine for metastatic disease?
• Population: 342 patients with metastatic pancreatic cancer, ECOG PS 0-1
• Results:
  • "Median overall survival: 11.1 vs 6.8 months (HR 0.57, pless than 0.001)"
  • "Median progression-free survival: 6.4 vs 3.3 months"
  • "Response rate: 31.6% vs 9.4%"
• Impact: Established FOLFIRINOX as first-line for fit patients with metastatic disease

4. MPACT (2013) - Gemcitabine + Nab-Paclitaxel [44]

• Question: Is Gem/Nab superior to gemcitabine for metastatic disease?
• Population: 861 patients with metastatic pancreatic cancer
• Results:
  • "Median overall survival: 8.5 vs 6.7 months (HR 0.72, pless than 0.001)"
  • "Median progression-free survival: 5.5 vs 3.7 months"
• Impact: Established Gem/Nab as first-line option (alternative to FOLFIRINOX)

5. POLO (2019) - Olaparib Maintenance in BRCA-Mutated [45]

• Question: Does olaparib maintenance improve PFS in germline BRCA-mutated metastatic pancreatic cancer after platinum-based therapy?
• Population: 154 patients with germline BRCA1/2 mutations, non-progressive after ≥16 weeks platinum therapy
• Results:
  • "Median progression-free survival: 7.4 vs 3.8 months (HR 0.53, p=0.004)"
• Impact: FDA-approved olaparib as maintenance; reinforced importance of germline testing

---

11. Patient and Layperson Explanation

What is Pancreatic Cancer?

The pancreas is an organ deep in your abdomen (tummy) that does two jobs: it makes enzymes to digest food, and it makes insulin to control blood sugar. Pancreatic cancer is when abnormal cells grow in the pancreas and form a tumor. It is one of the most serious types of cancer because it often spreads before causing symptoms.

Why is it Called the "Silent Killer"?

The pancreas is tucked behind your stomach and intestines. Cancers there can grow large without pressing on anything that causes pain or noticeable symptoms. By the time symptoms appear—like yellowing of the skin (jaundice) or severe back pain—the cancer has often spread to other organs like the liver.

What Are the Warning Signs?

• Yellow skin and eyes (jaundice): The tumor blocks the bile duct, causing bile to back up
• Unexplained weight loss: The cancer uses your body's energy and prevents proper food digestion
• Pain in the upper abdomen or back: The tumor presses on nerves
• New diabetes in someone over 60: The tumor damages the insulin-producing cells
• Pale, greasy stools: The pancreas cannot release enzymes to digest fat

How is it Diagnosed?

Your doctor will order a CT scan (a detailed X-ray) of your pancreas. This shows the tumor's size and whether it has spread. Sometimes an endoscopic ultrasound is done—a thin camera tube is passed down your throat to get very close images of the pancreas and take a tissue sample.

What is the Whipple Operation?

For tumors in the head of the pancreas that have not spread, the Whipple operation (pancreatoduodenectomy) is a major surgery that offers the only chance of cure. The surgeon removes:

• The head of the pancreas
• Part of the small intestine (duodenum)
• The gallbladder
• Part of the bile duct

Then the remaining organs are reconnected. It is complex surgery (5-8 hours) with a long recovery (2-3 months), but it can potentially cure the cancer if caught early enough.

What if Surgery Isn't Possible?

If the cancer has spread or is wrapped around major blood vessels, surgery cannot safely remove it all. In this case, treatment focuses on:

• Chemotherapy: Drugs to slow the cancer's growth and extend life
• Relieving jaundice: A small tube (stent) is placed in the bile duct to drain bile
• Pain control: Medications or nerve blocks to reduce pain
• Nutrition support: Pancreatic enzyme tablets (Creon) to help digest food

Why Do I Need Pancreatic Enzymes (Creon)?

The tumor blocks your pancreas from releasing digestive juices. Without these enzymes, food—especially fats—passes through undigested, causing greasy stools and weight loss. Taking Creon capsules with every meal and snack replaces these enzymes, helping you absorb nutrients and maintain your weight.

What is the Outlook?

Pancreatic cancer is very serious. If caught early and removed completely with surgery followed by chemotherapy, about 25-30% of patients are alive 5 years later. However, most cases are diagnosed late, when cure is not possible. In those cases, treatment focuses on extending life (typically 6-12 months with chemotherapy) and maintaining quality of life.

What Can I Do?

• Stop smoking: Smoking doubles the risk of pancreatic cancer
• Maintain a healthy weight: Obesity increases risk
• Report new symptoms: Especially jaundice, unexplained weight loss, or persistent abdominal pain in someone over 60
• Family history matters: If multiple family members have had pancreatic cancer, breast cancer, or ovarian cancer, genetic testing may be recommended

---

12. References

Primary Sources

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763

2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

3. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039-1049. doi:10.1056/NEJMra1404198

4. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10-27. doi:10.14740/wjon1166

5. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252-1261. doi:10.1053/j.gastro.2013.01.068

6. Khorana AA, Mangu PB, Berlin J, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541-2556. doi:10.1200/JCO.2016.67.5553

7. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406. doi:10.1056/NEJMoa1809775

8. Benson AB 3rd, Myerson RJ, Sasson AR. Pancreatic, neuroendocrine GI, and adrenal cancers. In: Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020:1280-1322.

9. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504-511. doi:10.1016/j.gastro.2005.05.007

10. Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology. 2018;155(3):730-739. doi:10.1053/j.gastro.2018.05.023

11. Kalb B, Sarmiento JM, Kooby DA, Adsay NV, Martin DR. MR imaging of cystic lesions of the pancreas. Radiographics. 2009;29(6):1749-1765. doi:10.1148/rg.296095506

12. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105-119. doi:10.3978/j.issn.2078-6891.2011.021

13. Luo G, Liu C, Guo M, et al. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg. 2017;265(4):800-805. doi:10.1097/SLA.0000000000001741

14. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford). 2008;10(5):371-376. doi:10.1080/13651820802291233

15. Carney CP, Jones L, Woolson RF, Noyes R Jr, Doebbeling BN. Relationship between depression and pancreatic cancer in the general population. Psychosom Med. 2003;65(5):884-888. doi:10.1097/01.psy.0000088588.23348.71

16. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004;5(11):655-663. doi:10.1016/S1470-2045(04)01606-7

17. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47(20):5501-5503. PMID:3308077

18. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694-9705. doi:10.3748/wjg.v22.i44.9694

19. Khawja SN, Mohammed S, Silberfein EJ, Musher BL, Fisher WE, Van Buren G 2nd. Pancreatic cancer disparities in African Americans. Pancreas. 2015;44(4):522-527. doi:10.1097/MPA.0000000000000323

20. Hu C, Hart SN, Polley EC, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018;319(23):2401-2409. doi:10.1001/jama.2018.6228

21. Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009;101(6):424-431. doi:10.1093/jnci/djp020

22. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535-545. doi:10.1007/s00423-007-0266-2

23. Genkinger JM, Spiegelman D, Anderson KE, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer. 2011;129(7):1708-1717. doi:10.1002/ijc.25794

24. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328(20):1433-1437. doi:10.1056/NEJM199305203282001

25. Gupta S, Wang F, Holly EA, Bracci PM. Risk of pancreatic cancer by alcohol dose, duration, and pattern of consumption, including binge drinking: a population-based study. Cancer Causes Control. 2010;21(7):1047-1059. doi:10.1007/s10552-010-9533-6

26. Jiao L, Flood A, Subar AF, et al. Glycemic index, carbohydrates, glycemic load, and the risk of pancreatic cancer in a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1144-1151. doi:10.1158/1055-9965.EPI-08-1033

27. Streicher SA, Yu H, Lu L, Kidd MS, Risch HA. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1254-1263. doi:10.1158/1055-9965.EPI-13-1284

28. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008;1(4):306-316. PMID:18787611

29. Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018;8(9):a031435. doi:10.1101/cshperspect.a031435

30. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15(14):4674-4679. doi:10.1158/1078-0432.CCR-09-0227

31. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47-52. doi:10.1038/nature16965

32. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-327. doi:10.1056/NEJMoa1903387

33. Humphris JL, Patch AM, Nones K, et al. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017;152(1):68-74. doi:10.1053/j.gastro.2016.09.060

34. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418-429. doi:10.1016/j.ccr.2012.01.007

35. Bapat AA, Hostetter G, Von Hoff DD, Han H. Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer. 2011;11(10):695-707. doi:10.1038/nrc3131

36. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014;270(1):248-260. doi:10.1148/radiol.13131184

37. Kitano M, Yoshida T, Itonaga M, Tamura T, Hatamaru K, Yamashita Y. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol. 2019;54(1):19-32. doi:10.1007/s00535-018-1519-2

38. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128-1137. doi:10.1056/NEJMsa012337

39. Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery. 2012;152(3 Suppl 1):S103-S111. doi:10.1016/j.surg.2012.05.015

40. Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763-1773. doi:10.1200/JCO.19.02274

41. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406. doi:10.1056/NEJMoa1809775

42. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-1024. doi:10.1016/S0140-6736(16)32409-6

43. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. doi:10.1056/NEJMoa1011923

44. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703. doi:10.1056/NEJMoa1304369

45. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-327. doi:10.1056/NEJMoa1903387

46. Artifon EL, Aparicio D, Paione JB, et al. Biliary drainage in patients with unresectable, malignant obstruction where ERCP fails: endoscopic ultrasonography-guided choledochoduodenostomy versus percutaneous drainage. J Clin Gastroenterol. 2012;46(9):768-774. doi:10.1097/MCG.0b013e31825f264c

47. Domínguez-Muñoz JE, Drewes AM, Lindkvist B, et al. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. Pancreatology. 2018;18(8):847-854. doi:10.1016/j.pan.2018.09.016

48. Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev. 2011;(3):CD007519. doi:10.1002/14651858.CD007519.pub2

49. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. doi:10.1056/NEJMoa1000678

---

13. Examination Focus

Common Exam Questions

MRCP / FRACP Style

1. Question: A 68-year-old man presents with painless jaundice and a palpable non-tender gallbladder. What is the most likely diagnosis?

   • Answer: Carcinoma of the head of pancreas (Courvoisier's Law). The palpable gallbladder indicates malignant biliary obstruction rather than choledocholithiasis.

2. Question: What imaging sign is highly suggestive of a pancreatic head tumor?

   • Answer: Double duct sign - concurrent dilatation of the common bile duct (> 6mm) and main pancreatic duct (> 3mm).

3. Question: Why might CA 19-9 be normal despite extensive pancreatic cancer?

   • Answer: 5-10% of the population are Lewis antigen-negative (Le^a-b-) and cannot synthesize CA 19-9, resulting in false-negative results.

4. Question: What is the first-line chemotherapy regimen for metastatic pancreatic cancer in a fit patient (ECOG PS 0-1)?

   • Answer: FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin). Median survival 11.1 months vs 6.8 months with gemcitabine.

MRCS / FRCS Style

1. Question: What structures are resected in a Whipple's procedure (pancreatoduodenectomy)?

   • Answer: Pancreatic head, duodenum, distal common bile duct, gallbladder, ± distal stomach (if classical Whipple). Three anastomoses: pancreaticojejunostomy, hepaticojejunostomy, gastrojejunostomy.

2. Question: What is the most common complication after pancreatoduodenectomy?

   • Answer: Pancreatic fistula (15-25%), defined as drain fluid amylase > 3x serum on postoperative day 3.

3. Question: What defines R0 vs R1 resection?

   • Answer: R0 = negative margins (tumor > 1mm from resection edge). R1 = microscopic positive margin (tumor at or within 1mm). R0 associated with better survival.

4. Question: Why are high-volume centers recommended for pancreatic surgery?

   • Answer: Perioperative mortality 2-4% in high-volume centers (> 20 cases/year) vs 10-15% in low-volume centers. Also higher R0 rates and better long-term survival.

Oncology Viva

1. Question: Discuss the evidence for adjuvant chemotherapy after pancreatic resection.

   • Answer: PRODIGE 24 (2018) showed mFOLFIRINOX superior to gemcitabine: median OS 54.4 vs 35.0 months. ESPAC-4 (2017) showed Gem/Cap superior to gemcitabine alone: median OS 28.0 vs 25.5 months. Current standard: mFOLFIRINOX for fit patients, Gem/Cap for less fit.

2. Question: Which patients should receive PARP inhibitor therapy?

   • Answer: Germline BRCA1/2-mutated metastatic pancreatic cancer patients who have not progressed on platinum-based first-line chemotherapy (≥16 weeks). POLO trial showed olaparib maintenance improved PFS (7.4 vs 3.8 months). All pancreatic cancer patients should undergo germline testing.

3. Question: Compare FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for metastatic disease.

   • Answer: FOLFIRINOX: median OS 11.1 months (PRODIGE); more toxic (grade 3-4 45%); for ECOG PS 0-1, age less than 75. Gem/Nab: median OS 8.5 months (MPACT); better tolerated; for ECOG PS 0-2. No head-to-head trial; choice based on fitness/preferences.

Viva Points and Clinical Scenarios

Scenario 1: Borderline Resectable Disease

• Question: How do you define borderline resectable pancreatic cancer?
• Answer: SMA involvement ≤180°, or SMV/PV involvement > 180° or with contour irregularity but reconstructable. Current approach: neoadjuvant chemotherapy (FOLFIRINOX or Gem/Nab 2-4 months) → restage CT → surgery if converted to resectable. Goals: improve R0 rate, treat micrometastatic disease, select favorable biology.

Scenario 2: New-Onset Diabetes

• Question: A 72-year-old non-obese man develops diabetes. What cancer screening is indicated?
• Answer: New-onset diabetes in adults > 50 years warrants evaluation for pancreatic cancer. Approximately 50% of pancreatic cancer patients develop diabetes within 2 years of diagnosis. CT pancreas protocol indicated if: age > 50, non-obese, no family history of diabetes, concurrent weight loss.

Scenario 3: Trousseau's Syndrome

• Question: Why do pancreatic cancer patients develop recurrent thrombosis?
• Answer: Mucin-producing adenocarcinomas (including pancreatic) express tissue factor, activating coagulation cascade. Results in hypercoagulable state. Treatment: therapeutic LMWH (superior to warfarin in cancer patients). Consider prophylactic LMWH in ambulatory advanced pancreatic cancer patients.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists and multidisciplinary teams. Always refer to the most current evidence-based guidelines and local protocols.